⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
UPB News
Upstream Bio, Inc. Common Stock
Upstream Bio to Present New Data from Phase 2 VIBRANT Trial of Verekitug at the ATS 2026 International Conference
globenewswire.com
UPB
Form 8-K
sec.gov
UPB
Form 8-K
sec.gov
UPB
Upstream Bio Highlights Phase 3 Development Strategy for Verekitug and Reports Fourth Quarter and Full Year 2025 Financial Results
globenewswire.com
UPB
Chronic Rhinosinusitis with Nasal Polyps Market Shows Strong Upward Momentum During the Forecast Period (2026-2036) as Demand for Advanced Therapies Rises | DelveInsight
prnewswire.com
GSK
UPB
SNY
LLY
AZN
AMGN
REGN
PFE
MRK
TEVA
NVS
INSM
LYRA
Upstream Bio Presents Additional Analyses from the Phase 2 VIBRANT Trial of Verekitug in Chronic Rhinosinusitis with Nasal Polyps at 2026 AAAAI Annual Meeting
globenewswire.com
UPB
Upstream Bio to Present Additional Analyses from Phase 2 VIBRANT Trial in Chronic Rhinosinusitis with Nasal Polyps in Late-Breaking Session at AAAAI Annual Meeting 2026
globenewswire.com
UPB
Upstream Bio to Participate in Upcoming March Investor Conferences
globenewswire.com
UPB
Upstream Bio Reports Positive Top-line Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma
globenewswire.com
UPB
Upstream Bio to Host Webcast to Report Top-Line Results from the Phase 2 VALIANT Trial of Verekitug in Patients with Severe Asthma
globenewswire.com
UPB